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Abstract
Diabetes mellitus (DM) is a metabolic disorder and characterized by hyperglycemia. 
Being a concern of both the developed and developing world, diabetes is a global health 
burden and is a major cause of mortality world-wide. The most common is the type 2 
diabetes mellitus (T2DM), which is mainly caused by resistance to insulin. Long-term 
complications of diabetes cause microvascular related problems (eg. nephropathy, 
neuropathy and retinopathy) along with macrovascular complications (eg. cardiovas-
cular diseases, ischemic heart disease, peripheral vascular disease). Renin-angiotensin-
aldosterone system (RAAS) regulates homeostasis of body fluid that in turn, maintains 
blood pressure. Thus, RAAS plays pivotal role in the pathogenesis of long-term DM 
complications like cardiovascular diseases and chronic kidney diseases. T2DM is a 
polygenic disease, and the roles of RAAS components in insulin signaling pathway 
and insulin resistance have been well documented. Hyperglycemia has been found 
to be associated with the increased plasma renin activity, arterial pressure and renal 
vascular resistance. Several studies have reported involvement of single variants within 
particular genes in initiation and development of T2D using different approaches. This 
chapter aims to investigate and discuss potential genetic polymorphisms underlying 
T2D identified through candidate gene studies, genetic linkage studies, genome wide 
association studies.
Keywords: diabetes, type 2 diabetes, renin-angiotensin-aldosterone system, 
hypertension, gene polymorphism, genome wide association study, genetics, 
COVID-19
1. Introduction
Diabetes is a global health burden and one of the leading causes of morbidity 
world-wide [1]. Diabetes mellitus (DM) is a metabolic disorder characterized by 
polydipsia, polyphagia, polyurea and weight loss due to hyperglycemia, which 
means persistent elevated levels of plasma glucose. The prolonged hyperglycemia 
results in long-term impediments of diabetes that cause macrovascular complica-
tions including cardiovascular diseases (CVDs) and other vascular complications 
including nephropathy (end-stage renal disease) or retinopathy (leading to blind-
ness) [2]. On the other hand, renin-angiotensin-aldosterone system (RAAS) plays 
an important role in maintaining blood pressure and body fluid [3]. Inappropriate 
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activation of RAAS contributes to the hemodynamic abnormalities that lead to 
endothelial dysfunction, hypertension, and CVD [3, 4].
Diabetes, hypertension and CVDs, are important risk factors for severity and 
mortality in people infected with coronavirus infectious disease 2019 (COVID-19) 
[5, 6]. Both Type 2 diabetes (T2D), the commonest form of diabetes and hyperten-
sion are multifactorial and polygenic diseases caused by the association of both 
genetic and environmental factors. Understanding the underlying genetic causes of 
susceptibility to these diseases is important for people’s health and health-related 
quality of life worldwide. In this chapter, we describe the pathophysiology of T2D 
and RAAS and their associated risks analyzed in term of genetic variants.
2. Diabetes
Diabetes is a global epidemic affecting people of both the developed and devel-
oping world. According to International Diabetes Federation, 9.3% of the world 
population had diabetes in 2019 and predicted that by 2045 about 10.9% of the 
world population may suffer from diabetes [7]. Prevalence of diabetes is increasing 
both in developing and developed countries. About 79% of the diabetic patients live 
in low-income or lower middle-income countries of which more than 60% belongs 
to Asian countries while rest of them are habitant of developed world [8]. Notably, 
diabetes is a health concern in adults compare to other age groups and it has been 
projected that between the years 2010 to 2030, developing countries will harbor 
69% more adults with diabetes while 20% more adults with diabetes will be resid-
ing in developed countries [9]. Persistent elevated levels of plasma glucose result in 
long-term impediments of diabetes that cause macrovascular complications includ-
ing CVDs, peripheral vascular disease, stroke and microvascular complications 
including nephropathy that leads to end-stage renal disease, retinopathy leading to 
blindness, neuropathy that causes damage to the nerves [2].
Diabetes can be classified into the following types [10]:
i. Type 1 diabetes (T1DM; due to autoimmune β-cell destruction, usually 
leading to absolute insulin deficiency, including latent autoimmune diabetes 
of adulthood).
ii. Type 2 diabetes (T2DM; due to a progressive loss of adequate β-cell insulin 
secretion frequently on the background of insulin resistance).
iii. Gestational diabetes mellitus (diabetes diagnosed in the second or third 
trimester of pregnancy that was not clearly overt diabetes prior to gestation).
iv. Specific types of diabetes due to other causes, eg. monogenic diabetes 
syndromes (such as neonatal diabetes and maturity-onset diabetes of 
the young), diseases of the exocrine pancreas (such as cystic fibrosis and 
pancreatitis), and drug- or chemical-induced diabetes (such as with gluco-
corticoid use, in the Human Immunodeficiency Virus treatment, or after 
organ transplantation).
Of the major types, T2DM is the commonest form. T2D was caused by devel-
oping insulin resistance due to lifestyle, obesity, reduced physical activity [3]. 
Individuals with T2DM will have seven to ten years shorter life span compare to 
non-diabetic individuals and 80% patients with T2DM develop cardiovascular 
disease [11]. CVD like coronary artery disease is responsible for the 2–4 fold 
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increased rate of death in adults [12, 13]. Diabetes being considered as the inde-
pendent risk factor from other such factors as age, gender, smoking, weight for 
dying from liver disease, lung disease, cancer, mental disorders, cardiovascular 
complications [14]. Moreover, people are more prone to infections or infectious 
diseases who have already developed diabetes [15] due to high levels of glucose in 
blood that favors immune dysfunction by modulating both innate (alteration of 
neutrophil functions) and adaptive (reducing T cell response) immune response 
[16–20]. Most recent incidence of pandemic has revealed that the severity of 
COVID-19 exaggerates in individuals with hyperglycemia due to augmented 
production of pro-inflammatory cytokines as well as poor innate immunity [21]. 
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection 
severely affects the survival rate of the infected individuals [21] with diabetes as it 
is a critical comorbidity [22].
T2D is a multifactorial and polygenic diseases caused by the association of 
different risk alleles located on multiple genes. Environmental factors modulating 
gene–gene interaction and/or expression are believed to be contributing factor for 
the development of T2D. Thus, genetic variants associated with T2DM are not only 
important for prediction and prevention of the disease along with its associated 
complications, but also will facilitate early treatment as well as need-based bona 
fide management of the disease.
3. Renin-angiotensin-aldosterone system
RAAS is one of the multifaced systems, which maintains homeostasis of body 
fluids, electrolyte balance and thus, regulates blood pressure [3, 23, 24]. Renin, 
initially known as pressor hormone, is an aspartic protease and it’s only known 
substrate is angiotensinogen (AGT) [25]. Angiotensin converting enzyme (ACE) 
is a peptidase that is mainly found in the capillaries of lung followed by endothelial 
and kidney epithelial cells in human [26]. The classical RAAS involves cleavage of 
AGT for release of a small decapeptide, angiotensin-I (Ang-I). The peptidase ACE 
then converts Ang-I into an octapeptide, angiotensin-II (Ang-II). RAAS activity is 
intrinsically high in the lung where ACE level is very high and thus, a major site of 
systemic Ang-II synthesis.
The Ang-II is the most potent hormone peptide that utilizes G-protein coupled 
receptors (GPCRs) called angiotensin type 1 and type 2 receptors (AT1R and 
AT2R) to mediate physiological functions. Ang-II facilitates vasoconstriction, cell 
proliferation, cell hypertrophy, anti-natriuresis, fibrosis, and atherosclerosis using 
AT1R [27] while, via AT2R, the peptide elicits vasodilation, anti-proliferation, anti-
hypertrophy, anti-fibrosis, anti-thrombosis, and anti-angiogenesis [28] (Figure 1). 
Ang-II also stimulates the production of the steroid hormone, aldosterone, which is 
the final product of the RAAS cascade. Aldosterone binds to the mineralocorticoid 
receptor and regulates the transcription of target genes, resulting in the upregula-
tion of electrolyte flux pathways in the kidney. Dysregulation of RAAS can lead 
to adverse effects on fluid homeostasis, which in turn may lead to organ damage 
followed by CVDs.
Angiotensin converting enzyme 2 (ACE2) is a homolog of ACE. ACE2 is also 
highly expressed in the lung. The main activity of ACE2 is to degrade Ang-II into 
angiotensin 1–7 (Ang 1–7) by hydrolyzing of the C-terminal residue [29]. Thus, 
ACE2, in the lung, have a role in adjusting the balance of circulating Ang-II/Ang 1–7 
levels. Also, product of ACE2 facilitates vasodilation and therefore opposing the 
role of ACE product (i.e. Ang-II). Ang 1–7 is expected to exert its action through the 
MAS-related (MAS1) GPCR [30]. It is evident that insulin exhibits adverse effects 
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on the structural and functional features of islet cells by inducing Ang-II mediated 
oxidative stress [31]. Through AT1R, Ang-II inhibits course of insulin action in vas-
cular and skeletal muscle tissue, interferes insulin signaling via phosphatidylinositol 
3-kinase and its downstream protein kinase B (Akt) signaling pathway [32].
Increased vasoconstriction and renal sodium reabsorption along with enhanced 
secretion of aldosterone results overactivation of RAAS followed by metabolic 
modulation leading to altered blood pressure and development of insulin resistance 
[33, 34]. Aldosterone has the ability to impair insulin signaling pathway by down-
regulating insulin receptor substrate-1 (IRS-1) in vascular smooth muscle cells [35] 
and thus, contributes to the development of and/or deteriorating metabolic disor-
ders including disruption of glucose homeostasis [36].
The (pro)renin receptor [(P)RR], cloned almost two decades before in 2002 
[37], has now been considered as one of the pivotal members of RAAS. Modulation 
of renin/prorenin takes place after binding to their receptor. After binding to (P)
RR, the enzymatic activity of renin increases while the proactive form of renin 
known as prorenin gets activated non-proteolytically and exhibits renin activity 
[38, 39]. Binding to (P)RR with prorenin causes a change in conformation within 
the prosegment region followed by opening of the active site and making it acces-
sible to the substrate, AGT [39, 40]. Thus, receptor mediated activity of renin and 
prorenin possibly activate tissue specific renin-angiotensin system in an Ang-II 
dependent manner, which ultimately could contribute in modulating local RAAS. 
(P)RR has been found to be ubiquitously expressed in brain, heart, placenta, liver, 
pancreas and kidney [37]. The association between (P)RR gene polymorphism and 
high blood pressure has been demonstrated in Caucasian and Japanese male subjects 
[41, 42]. In another study with transgenic rats over expressing (P)RR in smooth 
muscles it was reported to elevate blood pressure and increase heart rate in their 
models [43]. A single mutation in exon 4 of (P)RR gene is associated with mental 
Figure 1. 
Renin-angiotensin-aldosterone system (RAAS) and its linkage to type 2 diabetes mellitus (T2DM). The 
classical RAAS shows angiotensin-II (Ang-II) dependent pathway mediated different physiological effects 
via G-protein coupled receptors (GPCR) called angiotensin type 1 and type 2 receptors (AT1R and AT2R). 
Renin, secreted from kidney, regulates the rate limiting step of this pathway by converting its liver originated 
substrate angiotensinogen (AGT) into a decapeptide, angiotensin-I (Ang-I). Ang-I is converted into an 
octapeptide Ang-II by angiotensin converting enzyme (ACE). Ang-II binds to AT1R and AT2R to mediate the 
counterbalanced physiological functions. Angiotensin converting enzyme 2 (ACE2) is to cleave Ang-II into 
angiotensin 1–7 (Ang 1–7), which exerts the vasodilation effects.
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retardation and epilepsy [44] while a silent mutation in exon 4 on human (P)RR 
facilitates enhanced expression of c321C > T that lacked exon 4 [44]. Though pres-
ence of this single nucleotide polymorphism (SNP) does not bring any change as far 
as the renin binding ability is concerned but it modulates ERK1/2 activation [44], 
which may in turn modifies gene expression pattern.
RAAS mediates diverse functions by the action of angiotensin receptors 
(Figure 1) and has the link to cancer through tissue remodeling, inflammation, 
angiogenesis and apoptosis [45, 46]. Genetic and epidemiological studies showed 
that polymorphism of the RAS components contribute to the risk of cancer. Either 
the insertion/deletion (I/D) polymorphisms of ACE or AGT M235T SNP confer the 
risks for developing breast cancer [45]. Two AT1R SNPs are associated with risk 
for renal cell cancer, and its associations are stronger in subjects with hypertension 
[47]. Although the identified SNPs could be a marker of disease linked to another 
disease-causing SNP, rather than the disease-causing SNP itself [47], further stud-
ies are warranted to clarify cancer etiology involving the RAS components.
4. Diabetes and RAAS
Development of insulin resistance at the cellular level is initiated by Ang-II and 
aldosterone via increasing oxidative stress and altering insulin signaling (Figure 2). 
Ang-II is also responsible for generating pancreatic β-cell oriented oxidative stress, 
inflammation, and apoptosis. Evidence also suggested involvement of aldosterone 
in diminished glucose induced insulin secretion from pancreas [33].
The therapeutic approaches for lowering glucose levels significantly reduces 
the chance of developing diabetes associated microvascular complications while 
modest improvement has been observed in case of improving diabetes associated 
macrovascular complications [48, 49]. A case–control study conducted in German 
population demonstrated increased prevalence of T2D among individuals with 
hypertension and higher concentration of aldosterone (but low Ang-II level and 
low plasma renin activity) compared to the control hypertensive individuals [50]. 
Figure 2. 
Involvement of RAAS components into pathogenesis of T2DM. Hyperglycemia causes oxidative stress 
through generation of reactive oxygen species (ROS) that along with the production of Ang-II through 
overactive RAAS, may contribute to the pathophysiology of T2DM. Thus, genetic polymorphisms present in 
the genes expressing the components of RAAS probably modulate gene expression followed by protein levels 
that ultimately involve in the disease pathogenesis. Also, variants within these genes may also involve in the 
initiation and development of diabetes.
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Another study revealed association between higher levels of aldosterone and insulin 
resistance along with dose-dependent contribution of high aldosterone level to 
the risk of developing T2D [51]. Figure 2 schematically represents components of 
RAAS involved in the regulation of physiology, and probable mechanism of their 
contribution to the pathophysiology of diabetes.
5.  T2DM and RAAS: contribution of the RAAS components to the 
pathogenesis of T2D
The most important key features of the pathogenesis of diabetes are the 
resistance to insulin which in turn reduces the insulin ability to uptake peripheral 
glucose [52], and the failure of β-cells to produce adequate amount of insulin [53]. 
Obesity is one of the major risk factors for the development of insulin resistance 
along with sedentary lifestyle, lack of physical activities etc. that in turn increases 
the levels of glucose in blood [54]. Obesity is also involved in the activation of RAAS 
[55, 56]. On the other hand, RAAS has been found to be associated with multiple 
obesity-associated chronic diseases, especially for cardiovascular related disease 
[57, 58]. In addition, several lines of evidence revealed association between activa-
tion of RAAS and the onset of T2D [55, 59, 60]. The connection between renin 
angiotensin system and insulin signaling pathway along with insulin resistance has 
been established [61]. A meta-analysis demonstrated that use of AT1R blockers or 
ACE inhibitors reduces the chance of new onset of T2DM by 22% in a population 
who are vulnerable to diabetes [62]. Though association between ACE I/D polymor-
phisms and risk of T2D inconsistent even in the same population [63, 64], CAPP 
trial demonstrated that ACE inhibitor captopril-treated patient group had 11% 
reduced chance of developing diabetes compared to non-treated groups [65] while 
LIFE study showed 25% reduction in new onset of diabetes [66]. All together these 
studies strongly support linkage between RAS components and hyperglycemia. 
Moderate hyperglycemia at the early stage of diabetes results increased plasma renin 
activity, arterial pressure and renal vascular resistance with the activation of both 
local and circulating RAAS [67, 68]. Moreover, hyperglycemia causes glycosylation 
of p53 which leads to the AGT transcription followed by the production of Ang-II 
[69, 70]. This was further supported by Fiordaliso et al. who demonstrated a direct 
correlation among levels of glucose, p53 glycosylation and Ang-II production [71].
Genetic predisposition involving certain SNPs residing within the genes of 
RAAS has been anticipated as the risk factors for the development and progres-
sion of T2D and T2D associated complications hypertension [72], coronary heart 
disease [73], nephropathy [73–75] and retinopathy [76]. Human AGT, a member 
of serpin gene family, comprises of 5 exons accounting for a full-length of about 
12 kb and is situated on chromosome 1 (1q42-q43). Most convincing evidence 
for the probable association of polymorphic sites within AGT gene with essential 
hypertension has been identified in the 5′ flanking region, exons, and introns of 
the gene [77]. Strong association of rs11568020 (A-152G) and rs5050 (A-20C) in 
the promoter region as well as rs4762 and rs699 within exon 2 of AGT gene with 
hypertension was evident in Eastern Indian population [72]. Interestingly, incom-
patible findings with respect to the association of AGT variants with T2D have 
been observed [62, 72, 78, 79]. Variants rs699 and rs4762 within AGT gene found 
to be associated with the reduced risk of T2D in Eastern Indian and Malaysian 
Malays populations [72, 78] while no significant association was observed in the 
Chinese and the Japanese populations [63, 79]. However, rs699, rs4762 and rs5051 
of AGT gene were reported to be associated with the increased risk of T2DM in the 
Pakistani [80], Korean [81] and Malaysian Malays [78] populations, respectively. It 
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has been documented that Ang-II is capable of stimulating the production of TGF-β 
[82] or inducing generation of reactive oxygen species (ROS) [83] that causes 
over-accumulation of extracellular matrix proteins or various cellular dysfunctions 
in patients with diabetes. Furthermore, variants present within the genes of RAAS 
components especially within ACE, AGT and AT1R genes have shown to be the 
most promising candidate genes susceptible to diabetic associated complications 
like nephropathy along with its progression towards renal failure as well as reti-
nopathy [78, 84]. Haplotype TCG of AGT has been observed to be associated with 
increased risk of T2D [78]. According to Purkait et al. [72], three haplotypes (H4, 
H7 and H8) of AGT showed strong association with hypertension while H2 had 
protective role against this disease. It is reported that the AT1R A1166C is not likely 
a risk factor for chronic kidney disease in East Asians and Caucasians while it is 
shown to be a risk factor in South Asian population [85, 86]. Almost 30–50% of the 
diabetic individuals are prone to develop kidney disease [87, 88]. Previous studies 
reported association of renin gene polymorphisms with number of non-commu-
nicable diseases including diabetic nephropathy [89], increased risk of vascular 
complications [90], plasma renin activity [91], susceptibility to hypertension in a 
variety of ethnic groups [92–95], T2D [96] with inconsistent results [97–99]. Few 
studies did not find any significant association of renin rs16853055 with diabetes 
and diabetic nephropathy diseases [100, 101] while Purkait et al. [102] found an 
association of this variant with diabetic nephropathy in Indian population along 
with strong linkage disequilibrium with rs16853055. On the other hand, Deinum et 
al. reported weak association of renin gene polymorphism present in the first intron 
(involved in the regulation of transcription of renin) with diabetic nephropathy 
[89, 103]. Moreover, rs1799998 of the CYP11B2 gene (aldosterone synthase) was 
associated with the levels of serum aldosterone and production [104, 105], blood 
pressure [106, 107], ischemic stroke [108], with the progression of renal function 
[109, 110] and end stage renal disease [111]. Meta-analysis performed by Xu et al. 
demonstrated association of allelic frequency as well as co-dominant homozygous 
and recessive models of inheritance with regard to −344 T/C polymorphism within 
promoter region of CYP11B2 gene with the increased risk of diabetic nephropathy 
[112]. Similar association was observed by Purkait et al. [113] in Indian population. 
Promoter regions play important regulatory roles in gene transcription followed 
by formation of a functional protein through translation. Thus, presence of vari-
ants within the promoter region may be involved in the disease progression or 
pathogenicity which is definitely subject to further investigation and validation. 
Furthermore, methylation within the promoter region of a gene contributes to the 
expression of that particular gene [114]. Variant rs1799998 causes substitution of 
cytosine to thymidine within the promoter region of CYP11B2 gene which is the 
binding site of a putative steroidogenic transcription factor-1 [115].
6. Pathophysiology and genetics of type 2 diabetes
Both environmental and genetic factors play pivotal role in the development of 
diabetes in human. However, some individuals develop diabetes while others do 
not although they use to live in the same environment. A substantial proportion of 
Pima Indians develop T2D even with a normal lifestyle in a normal environment 
that showed strong linkage of genetic make-up to T2D [116]. Thus, understanding 
genetics related to the pathogenesis of T2D is of utmost importance for the man-
agement of this global endemic disease. Familial studies orchestrated more robust 
data as proof that genes play important role as risk factor for the development of 
diabetes. First degree individuals with family history of T2D are at 3-fold increased 
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risk of developing T2D compared to those who do not have positive family history 
[117–119]. Studies with monozygotic twins demonstrated that 50% risk of develop-
ing type 1 diabetes is contributed by HLA genes while rest of the 50% is associated 
with environmental factors and epigenetic modifications [120, 121]. Several family, 
population and twin-based studies established that heritability of T2D ranges from 
20–80% [122, 123]. Forty percent individuals possess risk of developing T2D who 
have one parent with T2D while 70% of the individuals have higher risk of develop-
ing T2D if both the parents are T2D [124]. Seventy percent of monozygotic twins 
are in concordance with the chance of developing T2D while the concordance rate 
in dizygotic twins has been found to be 20–30% [125, 126].
The primary method to identify genes susceptible to T2D was genome link-
age analysis. This approach efficiently identified causal mutations specially for 
the monogenic forms of diabetes like maturity-onset diabetes in young (MODY), 
mitochondrial diabetes in neonates and insulin resistance [127–129]. This approach 
further recognized the short tandem repeats located on q arm of chromosomes 4, 5, 
10, 12, 22 and p arm of chromosomes 2, 3, 6, 13 for their probable association with 
T2D in different ethnic populations [130–134] along with causative genetic variants 
within calpain10 (CAPN10) [135], ENPP1 [136], HNF4A [137, 138] and ACDC [139]. 
Calcium-activated neutral protease 10, one of the regulator of glucose homeostasis, 
gene (CAPN10) variants UCSNP-43 G/A in intron 3, UCSNP-19 2R (two 32-bp 
repeats)/3R (three 32-bp repeats) in intron 6 and UCSNP-63 C/T in intron 13 have 
been reported to be associated with T2D in Mexicans Americans, German and 
Finnish populations [135, 140]. The ectonucleotide pyrophosphatase phosphodi-
esterase (ENPP1) was supposed to be associated with insulin resistance [141]. The 
three-alleles risk haplotype (K121Q/IVS20 delT-11/A > G + 1044 TGA, QdelTG) 
within ENPP1 was associated with childhood obesity, development of T2D and with 
adult obesity [136]. HNF4A, member of the steroid hormone receptor superfamily, 
plays major role in insulin expression and secretion followed by glucose metabolism 
in pancreatic β-cells along with gluconeogenesis in liver [142, 143]. Variants within 
HNF4A gene were identified as the risk factor for MODY and causative factor for 
β-cell dysfunctions [144]. Also, non-coding variants rs4812829 and rs6017317 as 
well as coding variant rs1800961 (T130I) within HNF4A were involved in the devel-
opment of T2D [145–147]. Decreased level of adipose tissue-derived adiponectin 
in plasma is evident in individuals with obesity [148], insulin resistance [149] and 
T2D [148]. Adiponectin encoding ACDC gene variants 276G > T and 45 T > G were 
found to be associated with lower levels of plasma adiponectin in Japanese [150] 
and German obese people [151], respectively along with their predisposition to 
T2D. However, genome wide linkage analyses did not reveal any association of these 
variants of ACDC gene with obesity and T2D in Pima Indians [139]. Transcription 
factor TCF7L2 showed strongest linkage to the risk of T2D before genome wide 
association study (GWAS) era [130]. TCF7L2 involves in Wnt signaling pathway 
that regulates proliferation and survival of pancreatic islet cell functions [152] and 
its reduced expression is linked to impaired insulin secretion [153]. TCF7L2 gene 
variants rs12255372 and rs7903146, showed strong linkage disequilibrium with 
composite at-risk alleles of the microsatellite marker (DG10S478).
Candidate gene association studies have also been proved to be effective to 
obtain substantial evidences of genetic predisposition to T2D. For example, insulin-
like growth factor 2 mRNA-binding protein 2 (IGF2BP2), an important candidate 
gene for T2D [154, 155], was involved with T2D development by reducing insulin 
secretion [156] may be through changing adipose tissue and β-cell function [157]. 
IGF2BP2 was also associated with overweight and obesity [158]. Association of 
rs4402960 and rs1470579 within IGF2BP2 with the risk of T2D demonstrated in 
French Caucasians while another study revealed that T2D patients carrying the 
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T allele of rs4402960 had higher levels of fasting plasma glucose, postprandial 
glucose, total cholesterol and postprandial serum insulin compared to individuals 
with the GG genotype [158]. Besides, IGF2BP2 variants showed effect on treatment 
of diabetes. For example, lower efficacy of the repaglinide treatment for reducing 
fasting plasma glucose and postprandial glucose was observed in diabetic patients 
with rs1470579 AC + CC genotypes compared to AA genotypes. On the other hand, 
repaglinide treatment had higher effect on diabetic patients with GT + TT geno-
types with regard to rs4402960 on postprandial insulin compared to GG genotype 
carrying patients [158]. The potassium inwardly rectifying channel, subfamily J, 
member 11 (KCNJ11) has attracted attention due to its contribution to the patho-
genesis of T2D by modulating insulin production and secretion [159] and thus, is 
a good candidate gene to elucidate its disease association. KCNJ11 harboring four 
missense SNPs rs5219, rs1800467, rs5215, rs41282930 were recognized to influence 
risk of T2D by impairing insulin secretion [160]. Peroxisome proliferator activator 
receptor gamma (PPARG) was identified to harbor T2D disease susceptibility vari-
ants. Both KCNJ11 and PPARG encode anti-diabetic drug targets and their respec-
tive missense SNPs rs5219 (E23K) and rs1801282 (P12A) are associated with the risk 
of T2D [161].
Although candidate gene and linkage analyses provided considerable evidences 
behind the genes for their probable association with the pathophysiology of T2D 
and/or with the risk of T2D, novel genes are yet demanding due to the inconsistent 
and discordant findings within the same population and also, in different ethnic 
groups. Screening of whole genome using GWAS helps to overcome the shortcom-
ings of the above mentioned approaches to some extent by expediting regularly 
spaced variants without any prior knowledge of gene or their effects that has 
brought a significant breakthrough in understanding the genetic basis of T2D. This 
has become realistic after successful completion of the Human Genome Project 
and the International HapMap Project. This has given an opportunity to deposit 
millions of SNPs in the public databases [162] and presence of higher frequency of 
a particular SNP in cases compare to controls suggests association of that SNP with 
the case i.e., disease. Moreover, to satisfy association of SNPs statistically, stringent 
p value (<10−8) is required in GWAS and it benefited researchers to eliminate false 
positive association out of the millions of reported SNPs [163]. Even with such strict 
threshold levels of statistics, several case–control studies in different ethnicities 
have generated replicative positive results through different independent datasets. 
T2D associated variants within genes uncovered by GWAS positioned at different 
chromosomal locations (Figure 3A) can be grouped into i) insulin secretion and 
processing related (GIPR, CCND2, CDKAL1, GCK, TCF7L2, GLIS3, THADA, 
IGF2BP2, DGKB), ii) impaired insulin function related (PPARG, KLF14, IRS1), 
iii) insulin resistance related (ACDC, FTO, KLF14, DUSP9), iv) β-cell mass and 
function related (IGF2BP2, HCNQ1, CDKN2A, CDKN2B) and iii) body mass 
index (BMI) and lipid level related (NRXN3, CMIP, APOE, and MC4R). Notably 
rs4731702 of intronless KLF14 demonstrated an association with insulin resistance 
[164] while rs972283 contributed to elevated blood pressure [165], which may 
ultimately increase risk of cardiovascular disease; C allele of the rs2283228 within 
HCNQ1 showed association with increased fasting glucose levels and impaired 
β-cell function in Asians [166], while C allele of rs2237895 in KCNQ1 was found 
to be related to decreased risk of abdominal obesity in patients with T2DM [167, 
168]; rs5945326 of DUSP9 on X chromosome was related to the increased risk 
of T2D in Japanese [169], Pakistanis [170] and in European [171] populations; 
rs1558902 within FTO showed correlation with the incidence T2D in humans even 
after adjusting the data with confounding factors such as age and BMI [172] and 
rs9939609 may modulate the risk of T2D by regulating other genes, an incidence 
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independent of BMI [173]; variants present within the tumor suppressor cyclin 
dependent kinase inhibitors, CDKN2A and CDKN2B, reported to be associated 
with T2D in Asians and Europeans [174–177]. rs10811661 of CDKN2A/2B is also, 
according to GWAS, linked to diabetes [178]; hematopoietically-expressed homeo-
box or HHEX gene variants rs11118745G/A, rs7923837A/G, and rs5015480C/T had 
been identified as risk factors for T2D in Japanese [179], German [180], Korean 
[181], Indian [182] populations. Association of a common variant, Trp325Arg 
within SLC30A8, with the risk of T2D [171, 183]  
Figure 3. 
Chromosomal locations of genes carrying variants (A) associated with β-cell function followed by insulin 
production and secretion (B), glucose utilization and homeostasis (C) along with glycemic traits and abnormal 
adipose tissue function (D) which all together may lead to T2D and of genes of major RAAS components. 
Several approaches specially GWASs identified several variants associated with pancreatic islet cell function 
followed by β-cell dysfunction, insulin secretion and processing (red), with development of insulin resistance 
followed by imbalanced glucose homeostasis (blue). Other variants are also associated with abnormal adipose 
tissue function which may also be caused by oxidative stress, a consequence of Ang-II (Figure 2). Variants 
within SLC30A8 and (P)RR (green) showed both protection against T2D and risk association with T2D as 
well as hypertension, respectively. Also, mostly non-coding and few coding variants within the genes (black) 
showed association with the risk of T2D. Variants within the major gene of RAAS have been found to be 
associated with the risk of T2D and T2D-associated hypertension other that their established risk association 
with essential hypertension and cardiovascular diseases. REN, renin; AGT, angiotensinogen; AT1R and AT2R, 
angiotensin type 1 and type 2 receptors, ACE, angiotensin converting enzyme; ACE2, angiotensin converting 
enzyme 2; CYP11B2, aldosterone synthase; (P)RR, (pro)renin receptor; In, insulin; Glc, glucose; IRS, insulin 
receptor substrate.
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and, levels of glucose [184] and proinsulin [185] had been well documented. 
Interestingly, through genotyping of ~150,000 individuals from five ethic groups, 
Flannick et al. (2014) revealed protective role against the development of T2D 
mediated by the loss of function variants harbored within SLC30A8 [186]. AA 
genotype of rs11558471 of SLC30A8 was found significantly more frequent in T2D 
patients than in controls in Han Chinese [187] and Indian [182] populations.
Non-coding variants within different genes [like variants of PRC1, MADD, 
MTNR1B, FADS1, CRY2, GLIS3, LC2A2, ADCY5, GCKR, G6CP2 [184], TP53INP1 
[188], GIPR [189], ADCY5 [189], TSPAN8/LGR5, JAZF1, Notch1 [190], HNF1B 
[191], FTO [155], ZEDB3 [188]], as presented in Figure 3A, were also recognized 
as major risk factors associated with the development of T2D and/or regulation 
of glucose/insulin homeostasis, and/or glycemic traits (Figure 3B and C) and 
abnormal adipose tissue function (Figure 3D) while few variants were discerned 
to have protective roles against the development of diabetes [184, 188–195]. Also, 
similar association was found with regard to intergenic variants rs972283 (G/A, 
47 kb upstream) of KLF14 [188], rs2943641 (C/T, 502 kb upstream) of IRS-1 
[155], rs1111875 (C/T, 7.7 kb downstream) of HHEX [183], rs10811661 (T/C, 
125 kb upstream) of CDKN2A/2B [190], rs4607103 (C/T, 38 kb upstream) of 
ADAMSTS9 [190], regulatory region variant rs5945326 (G/A, 8 kb upstream) 
of DUSP9 [188], rs2191349 (T/G) of DGKB/TMEM195 [196], promoter region 
rs2853669 of human telomerase reverse transcriptase (TERT) gene [197]. Non-
coding variants positioned at essential regions like enhancer and promoter 
sequence may also modulate chromatin loops, alter sequence motifs and modulate 
histone marks that ultimately regulate gene expression, which could be one of the 
key reasons their disease association.
7. Pathogenesis and genetics of RAAS
RAAS is the enzymatic cascade to produce the effector molecule, Ang-II, by the 
multiple enzymes [23] (Figure 1). Various genotypes of the RAAS components [eg. 
AGT, renin, ACE, ACE2, AT1R, AT2R and (P)RR] have been investigated to find the 
link between genetic variation, blood pressure, and hypertension [198].
The two AGT genotypes (G-6A non-coding SNP and M235T coding SNP) are 
associated with higher plasma AGT levels and increased risks of essential hyperten-
sion [77]. The AGT SNPs occurring within the non-coding region could explain 
the association with plasma AGT concentration because of the alternation in AGT 
transcription [198]. It is plausible that the higher AGT concentration brings about 
the higher levels of Ang-II, which may lead to high blood pressure. In the study of 
10,690 individuals, the associations of elevated blood pressure, ischemic heart dis-
ease and ischemic cerebrovascular disease were examined with four AGT variants 
(A-20C and G-6A non-coding SNPs and T174M and M235T coding SNPs) [199]. 
Both women and men with -6AA, 174TT, and 235TT (versus -6GG, 174TT, and 
235TT) had higher mean levels of plasma AGT (861 ng/mL and 811 ng/mL, respec-
tively). This finding suggests that the genotype has an effect on risk of elevated 
blood pressure in women, but not in men [199]. The association of the genotype 
with ischemic heart disease and ischemic cerebrovascular disease seems weak as a 
risk [199]. A meta-analysis of 45,267 individuals from different ethnic populations 
shows that M235T genotype is associated with an increase in plasma AGT levels 
[200]. An analysis of 424 individuals from 41 two-generation families from Utah 
indicates significant linkage between six AGT SNPs (rs5051, rs699, rs6687360, 
rs2478543, rs3789670 and rs943580) and plasma AGT levels whereas plasma AGT 
and blood pressure were not significantly correlated [201]. AGT SNPs have been 
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identified from various ethnic groups to show its association with hypertension 
[72, 202–205]. Of note, AGT genotypes (G-6A, T + 31C and M235T) with hyper-
tension are not associated with plasma AGT level, while -1074 t|T235 haplotype is 
associated with an increase of AGT level but not with hypertension [202]. Sato  
et al. [202] suggested that the positive association between AGT polymorphism and 
hypertension is not simply explained by an increase of plasma AGT concentration.
Renin polymorphism was investigated by assessing the association of ten renin 
genotypes with hypertension risk in 570 hypertensive and 222 normotensive 
Caucasians [95]. Subjects with DM, secondary hypertension, significant medical 
illness or severe obesity were excluded, and their food intakes were also controlled. 
The A allele of rs6693954 SNP and the haplotype containing rs6693954A were 
significantly associated with higher risk of hypertension [95]. Compared to other 
haplotypes, the same haplotype showed the higher levels of plasma renin activ-
ity, suggesting that a direct renin inhibitor is effective to reduce blood pressure of 
rs6693954A carriers [95]. In addition, the haplotype displayed a blunted mean arte-
rial pressure response to exogenously infused Ang-II [95], which infers the dysregu-
lation of RAAS at the tissue level [206]. This study [95] confirms the association 
between renin genotypes and risk for hypertension.
As described above, genetic variations in individual RAAS components can 
contribute to the onset of physiological outcomes, which probably brings about 
the increase in blood pressure. But hypertension is a multifactorial disease involv-
ing both genetic and environmental factors [207] like T2D. The mechanism of 
susceptibility to hypertension and CVD is much more complex, since various genes 
work in an additive or interactive manner, together with environmental factors 
[198]. Ji et al. (2013) [205] provided the experimental evidence to support the idea. 
In a study of 905 hypertensive and 905 normotensive Han Chinese population, 
41 SNPs of the five RAAS components (AGT, renin, ACE, AT1R, and CYP11B2) 
and the non-genetic factors were analyzed to investigate their associations with 
essential hypertension [205]. Subjects with CVD, DM, kidney diseases, secondary 
hypertension and other major chronic illnesses were excluded. Serum levels of total 
cholesterol and triglyceride, and BMI were significantly higher in the hypertensive 
group than in the normotensive group. Six SNPs (rs3789678 and rs2493132 within 
AGT, rs4305 within ACE, rs275645 within AT1R, rs3802230 and rs10086846 within 
CYP11B2) were shown to associate with hypertension. The interaction between BMI 
and rs4305 (ACE SNPs) increased the susceptibility to hypertension. Together with 
non-genetic factors, the genetic variations in the RAAS components may play an 
important role in determining an individual’s susceptibility to hypertension [205].
GWAS analysis performed by Ji et al. [208] provided one important viewpoint 
on genetic polymorphism of RAAS. The authors searched GWAS Catalog (https://
www.ebi.ac.uk/gwas/) and identified all known RAAS genes and relevant diseases 
and traits. Remarkably, SNPs within AGT, renin, ACE2, CYP11B2, ATP6AP2 [(P)
RR] and HSD11B2 were not associated with any disease and trait. There were SNPs 
being associated with other disease and trait: ACE (metabolic traits), AT1R (leads 
levels in blood), AT2R (fibrosis), MAS1 (lipoprotein levels), RENBP (schizophre-
nia) and NR3C2 (thyroid function). But these six SNPs showed no direct associa-
tion with hypertension. The only SNP associated with a blood pressure trait was 
rs17367504, which is located in the intronic region of methylenetetrahydrofolate 
reductase (MTHFR) gene near many plausible candidate genes, including ion chan-
nel CLCN6, natriuretic peptides NPPA and NPPB, and RAAS component AGTRAP. 
The authored emphasized that the contribution of RAAS variants needs to be 
reconsidered when evaluating one’s susceptibility of hypertension [208]. GWAS 
analysis is providing a new dimension for understanding genetic architecture of 
blood pressure and Page’s “mosaic theory” of hypertension [209].
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SARS-CoV-2 has emerged in December 2019, which caused COVID-19. The 
SARS-CoV-2 spike protein directly binds to ACE2, which is present on lung epithelial 
cells and other tissues [210]. ACE2 converts Ang-II to Ang 1–7 leading to tissue repair 
signal (Figure 1). When SARS-CoV-2 is attached to ACE2, it likely reduces the ACE2 
activity associated with reduced inflammation, thereby increasing lung injury due to 
the decrease in Ang 1–7 generation [210]. It was observed that the severe COVID-19 
patients are likely to have a history of diabetes, hypertension or CVD [5, 6]. For reduc-
ing the infection by COVID-19 and the other coronaviruses, deciphering the suscep-
tibility to hypertension in term of genetic variations should be indispensable, which 
will be achieved by steady efforts to clarify the genetic background of each ethnic.
We recently reported probable association of five non-coding SNPs within 
renin and (P)RR genes with T2D, hypertension and T2D-associated hyperten-
sion in Bangladeshi population [211]. Renin SNP rs3730102 was associated with 
an increased risk of the three diseases. Renin SNP rs11571079 was associated 
with an increased risk for hypertension and T2D-associated hypertension, while 
the SNP showed a decreased risk for T2D, exerting a protective effect. (P)RR 
rs2968915|rs3112298 haplotypes were related to an increased risk of T2D and T2D-
associated hypertension. These findings highlight important roles of non-coding 
variants of renin and (P)RR genes in the etiology of several polygenic diseases [211]. 
Although there is a limitation for genotyping the candidate SNPs for the disease risk 
prediction, finding the candidate gene in different ethnic group through “one-
to-one” approach should be valuable to design a measure for ensuring health and 
quality of life at all ages in each population group.
8. Conclusion
Though several studies have revealed genetic approaches to identify the patho-
physiology of diabetes, hypertension and/or diabetes associated complications, it 
is still very challenging to uncover a definite candidate for the genetic etiology of 
these diseases due to overlapping involvement of genes, loci or even SNPs. GWASs 
have come forward to get rid of this elusiveness through scanning of whole genome. 
However, it is still very challenging due to the ethnic variations and ethnicity-
dependent gene expression patterns even harboring the same loci and/or variants 
to recognize genetic risk factors. Rather panels of variants (panels of variants for 
more closely related to T2D, panels for more closely related to hypertension and 
panels of overlapping variants in case of T2D and hypertension) could be a more 
meticulously related suggestive diagnostic, predictive and prognostic biomarker for 
these diseases. Known variants along with their gene expression pattern may play a 
pivotal role in determining disease pathogenesis.
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